

### Disclosure of Directors and Senior Managers Relevant Interests

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	7 March 2022
Date of last disclosure:	20 September 2021
Director or senior manager giving disclosure	
Full name(s):	Andrew Robert Donald Somervell
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	Not Applicable
Position held in listed issuer:	Vice President - Products & Technology
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)	
Class of affected quoted financial products:	Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial interest in shares issued to a trustee under an Employee Share Scheme
For that relevant interest	1 7
Number held in class before acquisition or disposal:	67.800
Number held in class after acquisition or disposal:	67,888
Current registered holder(s):	Andrew Robert Donald Somervell
Registered holder(s) once transfers are registered:	Andrew Robert Donald Somervell
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)	,
Type of affected derivative:	Not Applicable
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	One

Details of transactions requiring disclosure-	
Date of transaction: Nature of transaction:	28-Jan-20
Nature of transaction.	Participation in Employee Share Purchase Scheme Fisher & Paykel Healthcare Employee Share Purchase
Name of any other party or parties to the transaction (if known):	Trustee Limited
The consideration, expressed in New Zealand dollars, paid or received for the acquisition	
or disposal. If the consideration was not in cash and cannot be readily converted into a	
cash value, describe the consideration:	\$1,490.81
Number of financial products to which the transaction related:  If the issuer has a financial products trading policy that prohibits directors or senior	88
managers from trading during any period without written clearance (a closed period)	
include the following details—	
Whether relevant interests were aquired or disposed of during a closed period:	Not applicable
Whether prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	(a) Options to acquire Ordinary Shares (b) Peformance Share Rights
Nature of relevant interest:	(a) Beneficial (b) Beneficial
For that relevant interest.	(b) Beneficial
To that relevant interest,	(a) 144,323
Number held in class:	(b) 42,631
	Andrew Behad Danield Community
Current registered holder(s):	Andrew Robert Donald Somervell
For a derivative relevant interest,-	N. C. P. LL
Type of derivative:	Not applicable
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Cerification	
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	aroslu
Date of signature:	7 March 2022
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	



### Disclosure of Directors and Senior Managers Relevant Interests

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	7 March 2022
Date of last disclosure:	7 March 2022
	1 11141 011 2022
Director or senior manager giving disclosure	
Full name(s):	Andrew Robert Donald Somervell
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	Not Applicable
Position held in listed issuer:	Vice President - Products & Technology
Summary of acquisition or disposal of relevant interest (excluding specified derivative	·
Class of affected quoted financial products:	Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial interest in shares issued to a trustee under an Employee Share Scheme
For that relevant interest	
Number held in class before acquisition or disposal:	90,887
Number held in class after acquisition or disposal:	90,922
Current registered holder(s):	Andrew Robert Donald Somervell
Registered holder(s) once transfers are registered:	Andrew Robert Donald Somervell
Summary of acquisition or disposal of specified derivatives relevant interest (if applications)	able)
Type of affected derivative:	Not Applicable
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal  Total number of transactions to which notice relates:	One
rotal names of transactions to wind notice (Slates.	, , One

Details of transactions requiring disclosure-	
Date of transaction:	28-Feb-22
Nature of transaction:	Participation in Employee Share Purchase Scheme
Name of any other negligible to the transaction (if Irrayan).	Fisher & Paykel Healthcare Employee Share Purchase
Name of any other party or parties to the transaction (if known):  The consideration, expressed in New Zealand dollars, paid or received for the acquisition	Trustee Limited
or disposal. If the consideration was not in cash and cannot be readily converted into a	
cash value, describe the consideration:	\$491.96
Number of financial products to which the transaction related:	35
If the issuer has a financial products trading policy that prohibits directors or senior	
managers from trading during any period without written clearance (a closed period)	
include the following details—	
Whether relevant interests were aquired or disposed of during a closed period:	Not applicable
Whether prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	(a) Options to acquire Ordinary Shares (b) Peformance Share Rights
Nature of relevant interest	(a) Beneficial (b) Beneficial
Nature of relevant interest:	(b) Beneficial
For that relevant interest,-	
	(a) 109,826
Number held in class:	(b) 25,656
Current registered holder(s):	Andrew Robert Donald Somervell
For a derivative relevant interest,-	
Type of derivative:	Not applicable
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant	
interest in the derivative:	
Cerification	
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	aroslu
Date of signature:	7 March 2022
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	
	t



### Disclosure of Directors and Senior Managers Relevant Interests

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	7 March 2022
Date of last disclosure:	20 September 2021
Director or senior manager giving disclosure	
Full name(s):	Lewis George Gradon
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	Fisher & Fayker Fleatificare Corporation Limited
Position held in listed issuer:	Chief Executive Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivative	s)
Class of affected quoted financial products:	Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial interest in shares issued to a trustee under an Employee Share Scheme
For that relevant interest:	
Number held in class before acquisition or disposal:	562,280
Number held in class after acquisition or disposal:	562,351
Current registered holder(s):	Lewis George Gradon; Gradon Family Trust
Registered holder(s) once transfers are registered:	Lewis George Gradon; Gradon Family Trust
Summary of acquisition or disposal of specified derivatives relevant interest (if applications)	able)
Type of affected derivative:	Not Applicable
Class of underlying financial products:	
Details of affected derivative:	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative:	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant	
interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	One
Details of transactions requiring disclosure:	20.5.1
Date of transaction:	28 February 2022
Nature of transaction:	Participation in Employee Share Purchase Scheme
	Fisher & Paykel Healthcare Employee Share
Name of any other party or parties to the transaction (if known):	Purchase Trustee Limited
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:	¢4.405.03
Number of financial products to which the transaction related:	\$1,495.92 71

If the issuer has a financial products trading policy that prohibits directors or senior	
managers from trading during any period without written clearance (a closed period) include the following details:	
Whether relevant interests were acquired or disposed of during a closed period:	Not Applicable
Whether prior written clearance was provided to allow the acquisition or disposal to	
proceed during the closed period:	
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal	
Class of quoted financial products:	(a) Options to acquire Ordinary Shares (b) Peformance Share Rights
Nature of relevant interest:	(a) Beneficial (b) Beneficial
For that relevant interest:	
Number held in class:	(a) 282,391 (b) 91,787
Current registered holder(s):	Lewis George Gradon
For a derivative relevant interest:	
Type of derivative:	Not Applicable
Details of derivative:	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest:	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Certification	
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	L Grado
Date of signature:	7 March 2022
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	



### Disclosure of Directors and Senior Managers Relevant Interests

To NZX Limited; and	
Name of listed issuer:	Fisher 9 Devided Use Whence Commention Limited
Date this disclosure made:	Fisher & Paykel Healthcare Corporation Limited 7 March 2022
Date of last disclosure:	3 September 2021
Director or senior manager giving disclosure	,
Full name(s):	Lyndal Jane York
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Chief Financial Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives	
Class of affected quoted financial products:	Ordinary shares
Nature of the affected relevant interest(s):	Beneficial interest in shares issued to a trustee under an Employee Share Scheme
For that relevant interest	Employee chare continu
Number held in class before acquisition or disposal:	1,000
Number held in class after acquisition or disposal:	1,044
Current registered holder(s):	Alexander Eric York, Fisher & Paykel Healthcare Employee Share Purchase Trustee Limited
Registered holder(s) once transfers are registered:	Alexander Eric York, Lyndal Jane York (on completion of three year holding period)
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)	ole)
Type of affected derivative:	Not Applicable
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	One
Details of transactions requiring disclosure-	00.1 0000
Data of transaction:	28 January 2020

Name of any other party or purties to the transaction (if known):  The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in each and cannot be readily by converted into a cash value, describe the consideration was not in each and cannot be readily by converted into a cash value, describe the consideration was not in each and cannot be readily by converted into a cash value, describe the consideration of the continued the following destals—  Whether prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period:  Whether prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period:  Whether prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period:  Whether prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period:  Whether prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period:  Whether prior written clearance (if any):  Summary of other relevant interests.  Class of quoted financial products:  For that melivant interest.  (b) Perior manuscriber (if any):  North Applicable  Current registered hosters:  (c) Perior manuscriber (if any):  North Applicable (if any):  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  The prior's appoint of the derivative (if any):  The prior's appoint of the derivative (if any):  A statement as to whether the derivative (if any):  The prior's appoint of the derivative (if any):  Any other dealist needed to understand how the amount of the consideration payable under the derivative or the value of the derivative (if any):  The prior's appoint or the value of the derivative (if any):  Any other dealist needed to unders	Nature of transaction:	Participation in Employee Share Purchase Scheme
The consideration, expressed in New Zealand oblairs, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:  44  45  46  47  48  48  49  49  49  49  40  40  40  40  40  40		1 ' 1
or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:  At 349.7.70  Number of financial products to which the transaction related:  If the issuer has a financial products rading policy that prohibits directors or senior includes the following designed and products rading policy that prohibits directors or senior includes the following designed of the product within clearance (if other products the following designed of during a closed period)  Member prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period.  Summary of other relevant interests after acquisition or disposal to proceed during the closed period.  Summary of other relevant interests after acquisition or disposal:  Class of quoted financial products:  (a) Options to acquire Ordinary Shares (b) Performance Share Rights (b) Performance Share Rights (c) Beneficial Port of the relevant interest.  (b) Beneficial Courrent registered holder(s):  The off the relevant interest.  Not Applicable  Current registered holder(s):  The ordinary shares (b) Performance Share Rights (c) 9 a dot 6 great registered holder(s):  The ordinary shares (b) Performance Share Rights (c) 9 a dot 6 great registered holder(s):  The ordinary shares (c) 9 a dot 6 great registered holder(s):  The ordinary shares (c) 9 a dot 6 great registered holder(s):  A statement as to whether the derivative (if any) or the notional amount of underlying financial products.  A statement as to whether the derivative (if any):  The prices appecting terms (if any):  The prices appecting terms (if any):  The prices appecting terms (if any):  The director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  The director or senior manager is not a party to the derivative (if the relevant interest in t		Trustee Limited
Support   State   St	1 ''	
Number of financial products to which the transaction related:  'The issuer has a financial products trading policy that prohibits directors or senior managers from trading during any pend without written clearance (a closed period) include the foliotistic gleatis—  Whether relevant interests were aquired or disposed of during a closed period:  Whether relevant interests are acquisition or disposal to proceed during the closed period:  Date of the prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period:  Summary of other relevant interests after acquisition or disposal:  Class of quoted financial products:  (a) Options to acquire Ordinary Shares (b) Performance Share Rights  (a) Beneficial (b) Beneficial (b) Beneficial (c)		\$497.70
Number of fearchest interest.  Class of quoted financial products to which the transaction related:  Whether relevant interests were aquired or disposed of during a closed period. include the following details—  Whether relevant interests were aquired or disposed of during a closed period.  Whether prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period.  Summary of other relevant interests after acquisition or disposal:  Summary of other relevant interests after acquisition or disposals.  Class of quoted financial products:  (a) Options to acquire Ordinary Shares (b) Performance Share Rights  (a) Specifical (b) Performance Share Rights  (b) Performance Share Rights  (c) Performance Share Rights  (d) Options to acquire Ordinary Shares  (d) Performance Share Rights  (e) Performance Share Rights  (f) Performance Share Rights  (g) Performance S		*******
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period: include the following details—  Whether relevant interests were aquired or disposed of during a closed period:  Whether prior written clearance (if any):  Summary of other relevant interests after acquisition or disposal to proceed during the closed period:  Date of the prior written clearance (if any):  Summary of other relevant interests after acquisition or disposal:  (a) Options to acquire Ordinary Shares (b) Performance Shares Rights (a) Beneficial (b) Beneficial (b) Beneficial (b) Beneficial (b) Beneficial (c) B		44
managers from trading during any period without written clearance (a closed period) include the following details— Whether relevant interests were aquired or disposed of during a closed period: Whether prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period: Date of the prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period:  Summary of other relevant interests after acquisition or disposal:  Class of quoted financial products:  (a) Options to acquire Ordinary Shares (b) Performance Share Rights (b) Beneficial (c) Beneficia		
Mether relevant interests were aquired or disposed of during a closed period:  Whether relevant interests were aquired or disposed of during a closed period:  Whether prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period:  Date of the prior written clearance (if any):  Summary of other relevant interests after acquisition or disposal:  Class of quoted financial products:  Class of quoted financial products:  (a) Options to acquire Ordinary Shares (b) Performance Share Rights (b) Beneficial (b) Beneficial (b) Beneficial (c) Benefic		
Whether prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period:  Date of the prior written clearance (if any):  Summary of other rolevant Interests after acquisition or disposal:  Class of quoted financial products:  Class of quoted financial products:  (a) Options to acquire Ordinary Shares (b) Peformance Share Rights (b) Beneficial (b) Be		
Whether prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period:  Date of the prior written clearance (if any):  Summary of other rolevant Interests after acquisition or disposal:  Class of quoted financial products:  Class of quoted financial products:  (a) Options to acquire Ordinary Shares (b) Peformance Share Rights (b) Beneficial (b) Be	Whether relevant interests were aguired or disposed of during a closed period:	Not Applicable
Summary of other relevant interests after acquisition or disposal:  Class of quoted financial products:  Class of quoted financial products:  (a) Options to acquire Ordinary Shares (b) Petormance Share Rights (a) Semeficial (b) Petormance Share Rights (b) Petormance Share Rights (c) Semeficial (b) Semeficial (c) Semeficial (b) Semeficial (c) Semefic		
Date of the prior written clearance (if any):  Summary of other relevant interests after acquisition or disposal:  Class of quoted financial products:  (a) Options to acquire Ordinary Shares (b) Performance Share Rights (b) Performance Share Rights (c) Beneficial (d) Determined Share Rights (d) Performance Share Rights (d) Determined Share Rights (d) Determined Share Rights (d) Determined Share Rights (e) Performance Share Rights (d) Determined Share Rights (d) Determined Share Rights (d) Determined Share Rights (e) Performance Share Rights (d) Determined Share Rights (e) Performance Share Rights (d) Determined Share Rights (e) Determined		
Summary of other relevant interests after acquisition or disposal:  Class of quoted financial products:  (a) Options to acquire Ordinary Shares (b) Peformance Share Rights  (a) Beneficial  For that relevant interest.  (b) Peformance Share Rights  (c) Beneficial  (d) 29.781 (d) 29.781 (d) 9.406 (d) Quote Interest.  (e) 29.781 (d) 9.406 (d) Quote Interest.  (f) 9.406 (d) Quote Interest.  (g) 29.781 (g) 9.406 (d) Quote Interest.  (h) Peformance Share Rights  (g) Beneficial  (g) 29.781 (g) 9.406 (g) 9.406 (g) Quote Interest.  (h) Peformance Share Rights  (g) Beneficial  (h) Beneficial  (h) Beneficial  (h) Beneficial  (h) Beneficial  (h) Beneficial  (h) Peformance Share Rights  (h) Pefor Righ		
Class of quoted financial products:  (a) Options to acquire Ordinary Shares (b) Peformance Share Rights (a) Beneficial (b) Ben	Date of the prior written clearance (if any):	
Class of quoted financial products:  (a) Options to acquire Ordinary Shares (b) Peformance Share Rights (a) Beneficial (b) Ben		
Class of quoted financial products:  Nature of relevant interest.  For that relevant interest.  (a) Beneficial  For that relevant interest.  (b) Beneficial  (c) Beneficial  (d) Beneficial  (e) Beneficial  (f) Beneficial  (h) Peformatos Parks  (h) Parks all Parks  (h) Parks all Park	Summary of other relevant interests after acquisition or disposal:	
Nature of relevant interest:    (a) Beneficial		(a) Options to acquire Ordinary Shares
Nature of relevant interest:  For that relevant interest.  (a) 29,781 (b) 9,408  Current registered holder(s):  Details of derivative relevant interest.  Type of derivative:  Not Applicable  Not Applicable  Details of derivative (if any):  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative relevant interest.  For that derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Signature of director or officer:  Date of signature:  7 March 2022  or  Signature of person authorised to sign on behalf of director or officer:  Date of signature:	Class of quoted financial products:	( )
For that relevant interest.  Number held in class:  (a) 29,781 (b) 9,406 Current registered holder(s):  Lyndal Jane York For a derivative relevant interest.  Type of derivative:  Not Applicable  Details of derivative,  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  The price's specified terms (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative or the value of the derivative, the nature of the relevant interest.  Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Certification  Loertify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  7 March 2022  or  Signature of person authorised to sign on behalf of director or officer:  Date of signature:		
Number held in class: (a) 29,781 (b) 9,406 Current registered holder(s): Lyndal Jane York  For a derivative relevant interest,- Type of derivative:  Not Applicable  Details of derivative,- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: For that derivative relevant interest Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Signature of director or officer:  Date of signature:  7 March 2022  or  Signature of person authorised to sign on behalf of director or officer:  Date of signature:		(b) Beneficial
Number held in class: Current registered holder(s): Lyndal Jane York  For a derivative relevant interest,- Type of derivative:  Not Applicable  Details of derivative.  The notional value of the derivative (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: Por that derivative relevant interest,- Parties to the derivative relevant interest. Parties to the derivative: If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Serfication  Lertify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  7 March 2022  To Signature of person authorised to sign on behalf of director or officer:  Date of signature:	For that relevant interest,-	(-) 00 704
Lyndal Jane York	Number held in class:	
Type of derivative:  Details of derivative,  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,-  Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Cerification  I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  7 March 2022  or  Signature of person authorised to sign on behalf of director or officer:  Date of signature:		
Type of derivative:  Details of derivative,  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,-  Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Cerification  I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  7 March 2022  or  Signature of person authorised to sign on behalf of director or officer:  Date of signature:	- · · ·	,
Details of derivative,-  The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,-  Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Cerification  I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  7 March 2022  To Signature:		Not Applicable
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest  Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Cerification  I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  7 March 2022  or  Signature of person authorised to sign on behalf of director or officer:  Date of signature:		
A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest  Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Cerification  I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  7 March 2022  or  Signature of person authorised to sign on behalf of director or officer:  Date of signature:	·	
A statement as to whether the derivative is cash settled or physically settled:  Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest.  Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Cerification  I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  7 March 2022  7 March 2022  7 March 2022		
Maturity date of the derivative (if any):  Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest  Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Cerification  I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  7 March 2022  or  Signature of person authorised to sign on behalf of director or officer:		
Expiry date of the derivative (if any):  The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest,-  Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Cerification  I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  7 March 2022  To Signature of person authorised to sign on behalf of director or officer:		
The price's specified terms (if any):  Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest  Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Cerification  I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  7 March 2022  Tor  Signature of person authorised to sign on behalf of director or officer:  Date of signature:		
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest  Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Cerification  I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  7 March 2022  Tor  Signature of person authorised to sign on behalf of director or officer:  Date of signature:	Expiry date of the derivative (if any):	
under the derivative or the value of the derivative is affected by the value of the underlying financial products:  For that derivative relevant interest  Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Cerification  I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  7 March 2022  or  Signature of person authorised to sign on behalf of director or officer:  Date of signature:	1 1	
financial products:  For that derivative relevant interest,- Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Cerification  I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  7 March 2022  or  Signature of person authorised to sign on behalf of director or officer:  Date of signature:	1	
For that derivative relevant interest Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Cerification  I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  Signature:  Signature:  T March 2022  T March 2022  T March 2022		
Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Cerification  I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  Signature of person authorised to sign on behalf of director or officer:  Date of signature:	'	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:  Cerification  I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  T March 2022  or  Signature of person authorised to sign on behalf of director or officer:  Date of signature:		
Cerification  I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  Signature of person authorised to sign on behalf of director or officer:  Date of signature:		
Cerification  I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  Signature of person authorised to sign on behalf of director or officer:  Date of signature:		
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  Signature of person authorised to sign on behalf of director or officer:  Date of signature:	interest in the derivative.	
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  Signature of person authorised to sign on behalf of director or officer:  Date of signature:	Confilentian	
disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.  Signature of director or officer:  Date of signature:  Signature of person authorised to sign on behalf of director or officer:  Date of signature:		
for whom it is made.  Signature of director or officer:  Date of signature:  Signature of person authorised to sign on behalf of director or officer:  Date of signature:		
Signature of director or officer:  Date of signature:  or  Signature of person authorised to sign on behalf of director or officer:  Date of signature:		
Date of signature:  or  Signature of person authorised to sign on behalf of director or officer:  Date of signature:	Tot Wildlink to Hiddo.	
Date of signature:  or  Signature of person authorised to sign on behalf of director or officer:  Date of signature:		, and the second
Date of signature:  or  Signature of person authorised to sign on behalf of director or officer:  Date of signature:	Signature of director or officer:	IMM -
or Signature of person authorised to sign on behalf of director or officer:  Date of signature:		
or Signature of person authorised to sign on behalf of director or officer:  Date of signature:		
Signature of person authorised to sign on behalf of director or officer:  Date of signature:	Date of signature:	7 March 2022
Date of signature:	or	
	Signature of person authorised to sign on behalf of director or officer:	
	Date of signature:	
Invarrie and live of authorised person:		
	ivame and title of authorised person.	



### Disclosure of Directors and Senior Managers Relevant Interests

To NZX Limited; and	
Name of listed issuer:	
	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	7 March 202
Date of last disclosure:	7 March 2022
Director or senior manager giving disclosure	
Full name(s):	Lyndal Jane Yori
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Chief Financial Office
Summary of acquisition or disposal of relevant interest (excluding specified derivatives	)
Class of affected quoted financial products:	Ordinary Share
Nature of the affected relevant interest(s):	Beneficial interest in shares issued to a trustee under a Employee Share Schem
For that relevant interest	. ,
Number held in class before acquisition or disposal:	1,04
Number held in class after acquisition or disposal:	1,119
Current registered holder(s):	Alexander Eric York, Fisher & Paykel Healthcare Employe Share Purchase Trustee Limite
Registered holder(s) once transfers are registered:	Alexander Eric York, Lyndal Jane York (on completion of three year holding period
Summary of acquisition or disposal of specified derivatives relevant interest (if applical Type of affected derivative:	ole) Not Applicable
Class of underlying financial products:	Тестириоди
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	One
Details of transactions requiring disclosure-	00.51
Date of transaction:	28 February 202

Nature of transaction:	Participation in Employee Share Purchase Scheme
	Fisher & Paykel Healthcare Employee Share Purchase
Name of any other party or parties to the transaction (if known):	Trustee Limited
The consideration, expressed in New Zealand dollars, paid or received for the acquisition	
or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	\$1,495.92
Number of financial products to which the transaction related:	71
If the issuer has a financial products trading policy that prohibits directors or senior	
managers from trading during any period without written clearance (a closed period) include the following details—	
Whether relevant interests were aquired or disposed of during a closed period:	Not applicable
Whether prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	(a) Options to acquire Ordinary Shares (b) Peformance Share Rights
	(a) Beneficial
Nature of relevant interest:	(b) Beneficial
For that relevant interest,-	
Number held in class:	(a) 69,624 (b) 22,741
Number neid in class.	(D) 22,741
Current registered holder(s):	Lyndal Jane York
For a derivative relevant interest,-  Type of derivative:	Not Applicable
Details of derivative,-	Not Applicable
The notional value of the derivative (if any) or the notional amount of underlying financial	
products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant	
interest in the derivative:	
Cerification	
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	une
Date of signature:	7 March 2022
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	
·	



## Disclosure of Directors and Senior Managers Relevant Interests

nited
2022
2021
earer
nited
eting
nares
er an
neme
,398
5,486
aykel nited
Trust
cable
able
cable

Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	One
Details of transactions requiring disclosure-	
Date of transaction:	28-Jan-20
Nature of transaction:	Participation in Employee Share Purchase Scheme
Name of any other party or parties to the transaction (if known):	Fisher & Paykel Healthcare Employee Share Purchase Trustee Limited
The consideration, expressed in New Zealand dollars, paid or recieved for the acquisition	
or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	\$1,490.81
Number of financial products to which the transaction related:	88
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—	
Whether relevant interests were aquired or disposed of during a closed period:	Not applicable
Whether prior written clearance was provided to allow the aquisition or disposal to	
proceed during the closed period:	
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal:	(a) Options to acquire Ordinary Shares
Class of quoted financial products:	(b) Peformance Share Rights
Nature of relevant interest:	(a) Beneficial (b) Beneficial
For that relevant interest,-	
	(a) 238,031
Number held in class:	(b) 78,983
Current registered holder(s):	Paul Nigel Shearer
For a derivative relevant interest,-	
Type of derivative:	Not Applicable
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial	
products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Cerification	
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	PaulSteare
Date of signature:	7 March 2022
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	



## Disclosure of Directors and Senior Managers Relevant Interests

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	7 March 2022
Date of last disclosure:	7 March 2022
Director or senior manager giving disclosure	
Full name(s):	Paul Nigel Shearer
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Senior Vice President - Sales & Marketing
Summary of acquisition or disposal of relevant interest (excluding specified derivative	ves)
Class of affected quoted financial products:	Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial interest in shares issued to a trustee under an Employee Share Scheme
For that relevant interest-	
Number held in class before acquisition or disposal:	384,897
Number held in class after acquisition or disposal:	384,968
Current registered holder(s):	Paul Nigel Shearer; Shearer Family Trust; Fisher & Paykel Healthcare Employee Share Purchase Trustee Limited
Registered holder(s) once transfers are registered:	Paul Nigel Shearer; Shearer Family Trust
Summary of acquisition or disposal of specified derivatives relevant interest (if appli	cable)
Type of affected derivative:	Not Applicable
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	One
Details of transactions requiring disclosure-	
Date of transaction:	28-Feb-22
Nature of transaction:	Participation in Employee Share Purchase Scheme
Name of any other party or parties to the transaction (if known):	Fisher & Paykel Healthcare Employee Share Purchase Trustee Limited
The consideration, expressed in New Zealand dollars, paid or recieved for the acquisition	
or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	\$1,495.92
Number of financial products to which the transaction related:	71
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—	
Whether relevant interests were aquired or disposed of during a closed period:	Not applicable
Whether prior written clearance was provided to allow the aquisition or disposal to	·
proceed during the closed period:	
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal:	(a) Options to acquire Ordinary Shares
Class of quoted financial products:	(b) Peformance Share Rights
	(a) Beneficial
Nature of relevant interest:	(b) Beneficial
For that relevant interest,-	(5) 426 204
Number held in class:	(a) 136,384 (b) 44,352
Current registered holder(s):	Paul Nigel Shearer
For a derivative relevant interest	
Type of derivative:	Not Applicable
	Not Applicable
Details of derivative,- The notional value of the derivative (if any) or the notional amount of underlying financial	
products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the	
underlying financial products:	
For that derivative relevant interest	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Cerification	
I certify that, to the best of my knowledge and belief, the information contained in this	
disclosure is correct and that I am duly authorised to make this disclosure by all persons	
for whom it is made.	
Signature of director or officer:	PaulSteare
Date of signature:	7 March 2022
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	